HSF2BP

Across TCGA pan-cancer cohorts, HSF2BP Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HSF2BP data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HSF2BP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HSF2BP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and SKCM are the cancer types where HSF2BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.162	0.685	.018	24	view →
UCEC	DFS	Median	All	1.000	0.624	.028	6	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HSF2BP–HNSC (OS)

Open the HNSC breakdown →